First three patients underwent successful implantation and clinical utilization of PortIO as part of a first-in-human study in Colombia, South America NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results